145 related articles for article (PubMed ID: 34669183)
1. Repository Corticotropin Injection (Acthar
Wirta D; McLaurin E; Ousler G; Liu J; Kacmaz RO; Grieco J
Ophthalmol Ther; 2021 Dec; 10(4):1077-1092. PubMed ID: 34669183
[TBL] [Abstract][Full Text] [Related]
2. Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease.
Toyos M; Toyos R; Jodoin B; Bunch R
Ophthalmol Ther; 2022 Jun; 11(3):1231-1240. PubMed ID: 35460497
[TBL] [Abstract][Full Text] [Related]
3. Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis.
Mirsaeidi M; Baughman RP; Sahoo D; Tarau E
Pulm Ther; 2023 Jun; 9(2):237-253. PubMed ID: 37072607
[TBL] [Abstract][Full Text] [Related]
4. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Askanase AD; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2020 Dec; 7(4):893-908. PubMed ID: 32996096
[TBL] [Abstract][Full Text] [Related]
5. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar
Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
[TBL] [Abstract][Full Text] [Related]
6. Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review.
Girman C; Panaccio MP; Hayes K; Niewoehner J; Wan GJ
Adv Ther; 2022 Jul; 39(7):3072-3087. PubMed ID: 35635646
[TBL] [Abstract][Full Text] [Related]
7. Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.
Askanase AD; Wright D; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2021 Dec; 8(4):1871-1886. PubMed ID: 34478124
[TBL] [Abstract][Full Text] [Related]
8. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse.
Kaplan J; Miller T; Baker M; Due B; Zhao E
Front Neurol; 2020; 11():598496. PubMed ID: 33414758
[No Abstract] [Full Text] [Related]
9. Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid Arthritis.
Fleischmann R; Hayes K; Ahn SW; Wan GJ; Panaccio MP; Karlsson D; Furst DE
Rheumatol Ther; 2022 Apr; 9(2):435-446. PubMed ID: 34919213
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Noninfectious Retinal Vasculitis Using Subcutaneous Repository Corticotropin Injection.
Anesi SD; Chang PY; Maleki A; Stephenson A; Montieth A; Filipowicz A; Syeda S; Asgari S; Walsh M; Metzinger JL; Foster CS
J Ophthalmic Vis Res; 2021; 16(2):219-233. PubMed ID: 34055260
[TBL] [Abstract][Full Text] [Related]
11. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
[TBL] [Abstract][Full Text] [Related]
12. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
[TBL] [Abstract][Full Text] [Related]
13. Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis.
Fleischmann R; Hayes K; Ahn SW; Wan GJ; Panaccio M; Karlsson D; Furst DE
Rheumatol Ther; 2022 Apr; 9(2):649-661. PubMed ID: 35184268
[TBL] [Abstract][Full Text] [Related]
14. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
15. Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial.
Fleischmann R; Furst DE; Connolly-Strong E; Liu J; Zhu J; Brasington R
Rheumatol Ther; 2020 Jun; 7(2):327-344. PubMed ID: 32185745
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of clinical outcomes in patients with dry eye disease using lubricant eye drops containing polyethylene glycol or carboxymethylcellulose.
Cohen S; Martin A; Sall K
Clin Ophthalmol; 2014; 8():157-64. PubMed ID: 24403819
[TBL] [Abstract][Full Text] [Related]
17. Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action.
Gillis T; Crane M; Hinkle C; Wei N
Open Access Rheumatol; 2017; 9():131-138. PubMed ID: 28790870
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of repository corticotropin injection for refractory cutaneous dermatomyositis: a prospective, open-label study.
Fernandez AP; Gallop J; Polly S; Khanna U
Rheumatology (Oxford); 2023 Nov; ():. PubMed ID: 37941470
[TBL] [Abstract][Full Text] [Related]
19. Repository corticotropin injection (H.P. Acthar gel) for the treatment of sarcoidosis-induced hypercalciuria and vitamin D dysregulation: a pilot, open label study.
Judson MA; Modi A; Ilyas F; Yucel R
Sarcoidosis Vasc Diffuse Lung Dis; 2018; 35(3):192-197. PubMed ID: 32476902
[No Abstract] [Full Text] [Related]
20. Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States.
Nelson WW; Lima AF; Kranyak J; Opong-Owusu B; Ciepielewska G; Gallagher JR; Heap K; Carroll S
J Ocul Pharmacol Ther; 2019 Apr; 35(3):182-188. PubMed ID: 30676837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
